In individuals with cancer, the levels of endothelial and circulating progenitor cells are often suppressed, particularly during the acute phase of treatment, and may remain lower in those receiving therapies targeting the vascular endothelial growth factor (VEGF) [67,68]. The gene discussed is VEGFA; the disease is cancer.